Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels

被引：11
|
作者：
Lujan, Juliana Velez [1 ]
Lengerke-Diaz, Paula A. [2 ]
Jacobs, Chaja [1 ]
Moreno-Cortes, Eider F. [2 ]
Ramirez-Segura, Cesar A. [2 ]
Choi, Michael Y. [1 ]
McCarthy, Colin [1 ]
Heinen, Alaina [1 ]
Kipps, Thomas J. [1 ]
Castro, Januario E. [1 ,2 ]
机构：
[1] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA
[2] Mayo Clin, Scottsdale, AZ USA
来源：
HAEMATOLOGICA | 2020年 / 105卷 / 01期
关键词：
MONOCLONAL-ANTIBODY; CLL PATIENTS; CHLORAMBUCIL; RELEASE;
D O I：
10.3324/haematol.2018.212597
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E22 / E25
页数：4
相关论文
共 50 条
  • [31] A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
    Woyach, Jennifer A.
    Ruppert, Amy S.
    Perez, Gabriela
    Booth, Allison M.
    Feldman, Diane
    Dib, Elie G.
    Jatoi, Aminah
    Le-Rademacher, Jennifer
    Heerema, Nyla A.
    Miller, Cecelia
    Lozanski, Gerard
    Little, Richard F.
    Hill, Brian T.
    Ding, Wei
    Stone, Richard M.
    Mandrekar, Sumithra J.
    Byrd, John C.
    BLOOD, 2021, 138 : 3728 - +
  • [32] Genetic Predictors of Ibrutinib-related Cardiovascular Side Effects in Patients with Chronic Lymphocytic Leukemia
    Hamadeh, Issam S.
    Patel, Jai N.
    Jacobs, Ryan
    Zeng, Hang
    He, Jiaxian
    Hu, Bei
    Moyo, Tamara Kay
    Soni, Amy
    Park, Steven
    Copelan, Ed
    Avalos, Belinda
    Hamilton, Alicia
    Steuerwald, Nury
    Ghosh, Nilanjan
    CLINICAL CANCER RESEARCH, 2023, 29 (23) : 4941 - 4948
  • [33] Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
    Woyach, Jennifer
    Ruppert, Amy S.
    Perez, Gabriela
    Booth, Allison M.
    Feldman, Diane
    Dib, Elie G.
    Jatoi, Aminah
    Le-Rademacher, Jennifer
    Heerema, Nyla A.
    Lozanski, Gerard
    Little, Richard
    Ding, Wei
    Hill, Brian T.
    Stone, Richard M.
    Mandrekar, Sumithra J.
    Byrd, John C.
    BLOOD, 2019, 134
  • [34] BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia
    Falchi, Lorenzo
    Baron, Jessica M.
    Orlikowski, Carrie Anne
    Ferrajoli, Alessandra
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2016, 8
  • [35] Characterization of bone marrow tumor associated macrophages in patients with chronic lymphocytic leukemia treated with Ibrutinib
    Strati, Paolo
    Schlette, Ellen
    Soto, Luisa Solis
    Duenas, Daniela
    Wistuba, Ignacio
    Burger, Jan
    CANCER RESEARCH, 2019, 79 (13)
  • [36] Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib
    Miller, Cecelia R.
    Ruppert, Amy S.
    Heerema, Nyla A.
    Maddocks, Kami J.
    Labanowska, Jadwiga
    Breidenbach, Heather
    Lozanski, Gerard
    Zhao, Weiqiang
    Gordon, Amber L.
    Jones, Jeffrey A.
    Flynn, Joseph M.
    Jaglowski, Samantha M.
    Andritsos, Leslie A.
    Blum, Kristie A.
    Awan, Farrukh T.
    Rogers, Kerry A.
    Grever, Michael R.
    Johnson, Amy J.
    Abruzzo, Lynne V.
    Hertlein, Erin K.
    Blachly, James S.
    Woyach, Jennifer A.
    Byrd, John C.
    BLOOD ADVANCES, 2017, 1 (19) : 1584 - 1588
  • [37] Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL)
    Akhtar, Othman S.
    Attwood, Kristopher
    Lund, Ian
    Hare, Ryan
    Hernandez-Ilizaliturri, Francisco J.
    Torka, Pallawi
    LEUKEMIA & LYMPHOMA, 2019, 60 (07) : 1650 - 1655
  • [38] Evaluation of safety outcomes with transitioning obinutuzumab from standard rate to short duration infusion in patients with chronic lymphocytic leukemia
    Fleck, Caroline
    Karabinos, Allison
    Cook, Allene
    Moore, Donald C.
    Jacobs, Ryan
    LEUKEMIA & LYMPHOMA, 2024, 65 (08) : 1198 - 1199
  • [39] Ibrutinib does not reverse disease- and treatment-related hypogammaglobulinaemia associated with chronic lymphocytic leukemia
    Khan, Sujoy
    Durairaj, Senthilkumar
    Phumphukhieo, Punyarat
    Holding, Stephen
    Allsup, David
    LEUKEMIA & LYMPHOMA, 2021, 62 (07) : 1786 - 1789
  • [40] OBINUTUZUMAB VS. IBRUTINIB IN THE TREATMENT OF TREATMENT-NAIVE PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA -A COST-COMPARISON STUDY IN COLOMBIA
    Vecino-Ortiz, A.
    Diaz-Sotelo, O. D.
    Rodriguez, M.
    Diaz-Toro, Y. R.
    Moreno-Silva, N. A.
    VALUE IN HEALTH, 2017, 20 (09) : A875 - A875
12345